Epidermal growth factor-urogastrone (EGF-URO) administered intraarterially was a potent dilator in dog femoral (FEM), superior (cephalic) mesenteric (SMA), celiac (CAC), coronary (COR), carotid (CAR), and renal (REN) vascular beds. The effects of EGF-URO, which exhibited tachyphylaxis, could not be attributed either to recirculating EGF-URO or to the secondary release ofother agonists or products ofthe cyclooxygenase pathway. Two vascular beds (FEM, SMA) showed a high maximum responsiveness to EGF-URO (maximum effect lEn,,,i 70% increase in flow) whereas another group (CAC, COR, CAR, and REN) exhibited lower responsiveness (E,, ,,-20%).
Introduction
Epidermal growth factor-urogastrone (EGF-URO)' is a mammalian polypeptide of -6,000 atomic mass units found in mice, rats, and a variety of other species including dogs and humans (for reviews, see references 1-4). EGF-URO was originally isolated either from male mouse submaxillary glands or from human urine on the basis of the polypeptide's ability to stimulate precocious eyelid opening or incisor eruption in newborn mice or to inhibit gastric acid secretion in dogs. EGF-URO is found in almost all body fluids under normal physiologic conditions (5) , but the exact nature of its physiological role, either during development or in the adult, is not clear (5) . Although many actions of EGF-URO have now been documented in a variety of cell culture systems (these effects range from the stimulation of membrane phosphorylation and DNA synthesis to the augmentation of prostaglandin production), few studies, except for those measuring the inhibition ofacid secretion, have been done to document the acute effects of EGF-URO in vivo. We were struck by the work ofScoggins and co-workers (6) who observed that adrenalectomized sheep on a basal replacement steroid infusion were unable to maintain their blood pressure when EGF-URO was administered intravenously at a rate of 125 Mg/h. The fall in blood pressure was attributed to a decrease in total peripheral resistance, accompanied by a compensatory increase in cardiac output and an increase in activity ofthe renin-angiotensin system. On the basis of this study in sheep, which was the first to indicate that EGF-URO could have an effect on the vasculature, we hypothesized that EGF-URO might play a role in the regulation of blood flow. Our own work (7) and the work of others (8) indicated, however, that EGF-URO can have a potent direct contractile effect on rat smooth muscle strips obtained either from the ileocolic artery (7) or from the aorta (8) . To explore the seemingly contradictory actions of EGF-URO on the vasculature, in the study we report here, we have examined the effects ofclose-arterially administered EGF-URO on regional blood flow in a number ofvascular beds (femoral, superior mesenteric, coronary, celiac, carotid, and renal) in the anesthetized dog. Further, we also report results of a study of the effects of EGF-URO in vitro on helical arterial strips, obtained from canine coronary arteries.
Methods
Materials. Reagents were obtained from the following suppliers and were used without further purification: acetylcholine chloride, histamine dichloride, indomethacin, DL-isoproterenol, diphenhydramine hydrochloride, all from Sigma Chemical Co. (St. Louis, MO); aminophylline from Squibb (Montreal, PQ); burimamide hydrochloride from Smith Kline & French, (Philadelphia, PA); naloxone hydrochloride from Dupont (Mississauga, ON); DL-propranolol from Ayerst (Montreal, PQ); and sodium pentobarbital from Allen and Hanbury (Toronto, ON). All other chemicals were of reagent grade or better. Indomethacin was solubilized with an equimolar amount of sodium carbonate in 0.9% (wt/vol) sodium chloride. All drugs were freshly diluted in 0.9% NaCl before administration. Mouse EGF-URO, purified from submaxillary glands exactly according to the procedure of Savage and Cohen (9) , yielded a single band upon gel electrophoresis in sodium dodecyl sulfate-containing polyacrylamide gels (15%) under reducing conditions and yielded a single peak upon reverse-phase liquid chromatography (C-18 column) using an acetonitrile gradient in 0.1% trifluoroacetic acid. Recombinant human urogastrone, kindly provided by Dr. H. Gregory, ICI Pharmaceuticals, Macclesfield, U.K., yielded a single band upon gel electrophoresis and was fully potent in a cultured cell mitogenesis assay. In a human fibroblast system, the ED" for the mouse and human EGF-URO routinely used in our laboratory is -0.25 ng/ml (10) .
Surgical procedures and measurements ofbloodflow. Mongrel dogs tobarbital (30 mg/kg i.v.). The animals were immediately intubated and ventilated with room air at 15 ml/kg per min. Additional pentobarbital was administered, as required, to maintain stable anesthesia. Routinely, the following parameters were continuously monitored as previously described (1 1, 12) and were recorded on a Gould 2800S recorder (Gould, Inc., Cleveland, OH): systemic arterial blood pressure, central venous pressure (Statham P23 DB transducers; Gould, Inc., Oxnard, CA), lead II electrocardiogram, and regional blood flow. All vessels used for monitoring regional blood flow were carefully dissected to avoid injury to the artery and the nerve supply and were fitted with electromagnetic flow probes attached to appropriately calibrated Micron RC 1000 flow meters (Micron Instruments, Los Angeles, CA). To measure coronary flow, the chest ofthe animal was opened through the fourth left intercostal space and a flow probe was placed around the left anterior descending coronary artery just after the bifurcation of the left circumflex coronary artery. To measure superior mesenteric flow, celiac flow, and renal flow, the abdominal cavity was approached via a midline incision, and flow probes were placed around the appropriate arteries as close as possible to the aorta. To measure carotid flow, a flow probe was placed around the left common carotid artery exposed through a left anterolateral cervical incision. The femoral flow was recorded from probes placed around the left and right femoral arteries exposed at the level of the inguinal fold. After completion of the surgical procedures, the animal was allowed to equilibrate for 60 min. At equilibration, baseline hemodynamic variables were: arterial blood pressure, systolic, 166±3.5 mm Hg (average±SEM); arterial blood pressure, diastolic, 128±3.6 mm Hg; central venous pressure, 4.2±0.2 mm Hg; femoral blood flow, 45±8 ml/min; mesenteric blood flow, 142±22 ml/min; celiac flow, 169±21 ml/min; renal blood flow, 171±15 ml/min; coronary blood flow, 31±5 ml/min; and carotid blood flow, 178±27 ml/min. EGF-URO, purified from male mouse submaxillary glands according to the procedure of Savage and Cohen (9) was administered close-arterially in a standard volume of 1 ml of 0.9% NaCi followed by a 1-ml saline flush. 2-ml saline injections were used as controls. The intraarterial injections of EGF-URO were made using hubless 27-gauge needles attached to 1-ml syringes by means of polyethylene tubing which had a dead space of 0.1 ml. The needles were left in situ, distal to the flow probes. Test doses ofEGF-URO (0.05-5.0 Mg) were administered in a random sequence. After each injection, the flow was allowed to return to the baseline value, and was equilibrated for an additional 15-min interval before the administration of the next test dose. Because of interanimal variability, and in keeping with usual practice (13) , all flows were normalized by expressing the vascular response to EGF-URO as a percent increase in flow (%I) relative to the baseline flow value. Test doses of sodium nitroprusside (0.1 g) were used to confirm that the EGF-URO-mediated increases in flow (maximum increase _ 70%) were well below the maximum responsiveness of the vascular bed (> 200% increase in flow caused by nitroprusside).
Effects ofsystemically administered blocking agents. The effects of a variety ofsystemically administered blocking agents on the stimulation ofblood flow by EGF-URO were evaluated by a previously used protocol (1 1, 12) . A test dose ofEGF-URO (1 Mg) was administered close-arterially (femoral artery) both before and after the intravenous administration of each blocking agent. The agents (burimamide, 1 mg/kg; diphenhydramine, 4 mg/kg; atropine, 1 mg/kg; naloxone, 20 ,g/kg; propranolol, 1 mg/kg; aminophylline, 10 mg/kg; and indomethacin, 5 mg/kg) were routinely administered intravenously in a random sequence that differed for each experiment. The blocking agents were administered slowly while monitoring the vital signs, which were kept within 5% of control values. The effectiveness of blockade was evaluated by the close-arterial administration of the appropriate agonists. Effective agonist blockade was observed with diphenhydramine (vs. histamine), atropine (vs. acetylcholine), propranolol (vs. isoproterenol), and naloxone (vs. beta endorphin). The doses ofaminophylline and indomethacin used are known to be effective inhibitors of purinergic metabolism and cyclooxygenase systems, respectively. The possibility that carryover effects of the blocking agents may have influenced data obtained in the sequential administration protocol was excluded by evaluating the effect of each blocking agent on the response to EGF-URO in animals which had received no other blocking drugs. In these control experiments, each blocking agent was individually tested in two animals; the protocol was unchanged from the sequential blockade experiments outlined above, wherein the response to EGF-URO was measured both before and after the administration of each blocking agent.
In vitro bioassay ofcanine coronary helical arterial strips. A preliminary survey showed that coronary arterial strips, which were as responsive as femoral-derived strips, provided the most reproducibly responsive tissue. Coronary strips offered the added advantage that the results could be compared with data obtained using material easily obtained at abatoirs from other species (cow, pig, or sheep); such comparative studies are ongoing in our laboratory. Thus, helical strips from the coronary artery were used for this study. Hearts of mongrel dogs of either sex, were obtained immediately after sacrifice. The left anterior descending and left circumflex coronary arteries were carefully dissected and placed in a petri dish containing physiological salt solution (PSS) which was aerated with a mixture of95% 02 and 5% CO2. PSS had the following composition (in millimolar) NaCI, 115; KCI, 4.7; CaCl2, 2.5; MgCl2, 1.2; NaHCO3, 25; KH2PO4, 1.2; dextrose, 10.0. Under a dissecting microscope, the arteries were trimmed of fat and adhering tissue. Sections ofthe arteries, which had an outer diameter between 2.0 and 2.5 mm, were cut into helical strips, -1.2 mm in width and 8 mm in length. Care was taken to avoid stretching ofthe arteries. The presence offunctional endothelium was demonstrated by the relaxation in response to 1 MM acetylcholine of strips precontracted with 30 mM KCl (14). In some experiments, the intimal side of the strips was gently rubbed over wetted filter paper and the loss ofintact endothelium was demonstrated by the lack ofa relaxing response to acetylcholine. The strips were mounted vertically in a plastic organ bath containing 3 ml of a PSS and propranolol (1 uM). In experiments where the preparations were assayed under calcium-free conditions, CaCl2 was omitted and replaced by 1.0 mM EGTA. The bath medium was maintained at 370C, pH 7.4, and was equilibrated with a gas mixture of 95% 02 and 5% CO2. A resting tension of 1.5 g (optimal for the response ofthe tissue to KC1 or norepinephrine [NE] ) was applied to the arterial strips, and the responses were recorded isometrically through force-displacement transducers (Statham UTC2) on a Gould 2400 S recorder. All preparations were equilibrated for 60 min before starting the experiments. Drugs were added directly to the bath and concentrations were calculated accordingly.
Results
Effects onfemoral bloodflow. In preliminary experiments, it was established that close-arterially administered EGF-URO caused an increase in blood flow in all arterial beds tested (femoral, superior mesenteric, coronary, celiac, carotid, and renal), without concomitant changes in systemic blood pressure, central venous pressure, or electrocardiogram. In that perfusion pressure did not change, an increase in blood flow was a direct measure of a decrease in regional vascular resistance. The femoral arterial bed was selected for a detailed study because of its high responsiveness and because of the availability of two comparable beds in a single animal. As illustrated in Fig. 1 (upper trace), the response to EGF-URO was slightly delayed, reaching a maximum within 2-6 min and persisting for up to 12-18 min. The response to EGF-URO exhibited marked tachyphylaxis, in that a second dose of EGF-URO, administered at a time when the response to the first dose had diminished by > 50%, did not cause a sustained elevation of flow, as did the first dose ( Fig. 1 , middle trace). Iftachyphylaxis were not present, one would have expected to observe an appreciable increase in flow 1.5 min after the second dose of EGF-URO; instead, at 1.5 min after the second dose of EGF-URO ( were not due to systemic production of some other vasoactive substance.
Effects of blocking agents. With attention focussed on the effects of EGF-URO on femoral blood flow, we evaluated the action of a variety of pharmacologic blocking agents, as summarized in Table I . The effectiveness ofsympathetic, cholinergic, and histaminergic blockade was assessed by the close-arterial administration oftest doses of isoproterenol (0.1 tg), acetylcholine (0.1 g), and histamine (0.1 g) both before and after the intravenous administration of the appropriate blocking agents.
None of the blocking agents tested (propranolol, atropine, diphenhydramine, burimamide, aminophylline, naloxone, and i.domethacin) significantly affected the ability of EGF-URO to increase blood flow either in the experiments where the blocking (Fig. 5) . The contractile response of propranolol-treated strips to 1.0 ,M NE (Fig. 5 A) was highly reproducible once the preparation had stabilized (the contraction shown in Fig. 5 A, represents exactly the response to three previous test doses of NE). If these strips were then preincubated for 10 min with EGF-URO, the subsequent response to NE was markedly inhibited (Fig. 5 B) . The response to 1 MiM NE in the absence of EGF-URO was 50% ofthe maximum NE-mediated contraction, which was obtained Figure 5 . Effects of EGF-URO in vitro in coronary arterial strips. Coronary helical arterial strips were prepared as described in the text. (Upper trace) Strips were repetitively contracted (four or more times) with 1 uM NE, in the presence of 1 uM propranolol, until a reproducible contraction was obtained. Tracing A is the same as the response to at least three previous test doses of NE. This contraction was taken as 100% (100% = 0.61±0.06 g, n = 30). Pretreatment with EGF-URO for 10 min caused a markedly attenuated response to 1 gM NE (B).
Subsequent repetition of the pretreatment procedure revealed that the strips acquired a significant tachyphylaxis for the effects of EGF-URO, in that a second (C) or third treatment (not shown) did not cause the same inhibition as the initial treatment. (Middle traces) Typical tracing of experiments in which the strips were incubated for 10 min in at NE concentrations around 100 AM. The inhibitory effect of EGF-URO showed considerable tachyphylaxis in that subsequent treatments with EGF-URO, even when they were spaced apart for up to 45 min, did not inhibit the NE-mediated contraction to the same extent as did the initial treatment (Fig. 5  C) . Further, EGF-URO was not able to cause a relaxation of tissue that had been precontracted by NE. Thus, dose-response curves for EGF-URO could only be done by adding the polypeptide to the organ bath before the agonist. In order to obtain accurate dose-response data, each individual strip was exposed to EGF-URO only once. Thus it was possible to obtain a doseresponse curve like the one shown in Fig. 6 . This inhibition of NE-mediated contraction did not depend on the presence ofan intact endothelium and could not be abolished by indomethacin (3 ;zM).
In calcium-free medium, EGF-URO did not cause either a direct contraction or relaxation. To examine the effects ofEGF-URO on the NE-mediated contraction in a Ca-free medium, the strips were incubated in Ca-free medium for 10 min before the addition ofNE. To replenish the intracellular calcium stores after contracting the strips with NE in the Ca-free medium, the bath medium was changed back to a Ca-containing PSS for 20 calcium-free medium prior to the addition of NE. Characteristically, the strips showed a reproducible initial phasic and a subsequent tonic responses to I AM NE. Shown are the phasic contractions in Ca-free medium in response to NE, before treatment with EGF-URO (D), and after treatment with EGF-URO (E). (Lower traces) Typical tracing of experiments in which the response was made dependent on the addition of Ca. Shown is a representative reproducible NE-mediated contraction in the presence of 2.5 mM Ca (F). The NE-mediated contraction was then made dependent on the addition of Ca (G) (note the same magnitude as if Ca had been present NE administration). The Ca-dependent contraction was then observed after pretreating the tissue for 10 min with EGF-URO (H). min ("Ca loading"); this procedure was repeated until a reproducible contraction was obtained. In Ca-free medium the response to 1 uM NE showed, as is described for other arteries (14), an initial phasic component, followed by a stable tonic plateau (Fig. 5 D) . The magnitude of the reproducible phasic contraction was taken as baseline value (0.12±0.02 g, n = 5). Preincubation with 10 ng/ml (1.6 nM) EGF-URO caused an inhibition of the phasic component of the NE-mediated contraction in Ca-free medium of 50.2 ± 6.5% (n = 5) (Fig. 5 E) . In some experiments, contraction was made dependent on the addition of Ca to the organ bath. First the strips were treated to obtain a reproducible response to 1 uM NE in a 2.5 mM Cacontaining PSS (Fig. 5 F) . Subsequently, the strips were incubated in Ca-free medium for 10 min. The addition of 1 AM NE showed the normal response to NE in a Ca-free medium (see Fig. 5 D) . We then added Ca. The response upon adding Ca (up to 2.5 mM) was the same in magnitude as ifCa had been present at 2.5 mM in the medium before NE administration (Fig. 5 G) . The strips were then Ca-loaded for 20 min and again incubated for 10 min in Ca-free medium, which also contained 30 ng/ml EGF-URO; NE (1 MM) was then added. Under these circumstances, the response upon adding Ca was much lower than the [EGF-URO] in ng/ml Figure 6 . Dose-response curve for the inhibitory effect of EGF-URO on the NE-mediated contraction of coronary helical arterial strips. The strips were treated to obtain a reproducible contraction in response to 1 MM NE. This control contraction was taken as 100% (100% = 0.61±0.06 g, n = 30). Then the strips were pretreated with EGF-URO for 10 min and again contracted with 1 AM NE. Each strip response of control strips that were not treated with EGF-URO (Fig. 5 H) . In summary, EGF-URO markedly inhibited the NEmediated contraction of canine coronary artery helical strips. This inhibition was observed both in Ca-containing and in Cafree medium and was also observed when NE-mediated contraction was made dependent on the addition of Ca to the organ bath.
Discussion
Our data document a potent vasodilatory action of EGF-URO that most likely results from a direct action of EGF-URO on arterioles. Characteristically, the time course of the response to EGF-URO (maximum at 2-6 min, persisting for up to 18 min) differed markedly from the time course of the response to other agonists such as isoproterenol and sodium-nitroprusside, which caused a rapid response lasting < 1 min. This observation suggests that EGF-URO probably does not act via the same pathways as these agonists. An effect of EGF-URO on nonmuscle cells (e.g., endothelial cells or neuronal elements) to release a vasodilatory substance responsible for the increased blood flow cannot be entirely ruled out. However, the information obtained with the pharmacologic blocking agents indicated that the vasodilatory action of EGF-URO did not appear to result secondarily from the release of known smooth muscle agonists (adrenergic, cholinergic, histaminergic, or purinergic) or from the release of endorphins or prostaglandins. In the experiments done in vitro EGF-URO did not cause a direct relaxation of canine vascular strips but inhibited the contractile effects of NE, when applied to the tissue before (but not after) the administration of NE. This inhibition of the response to NE was independent of the presence of functional endothelium, suggesting that in vitro EGF-URO exerts its effect directly on the smooth muscle cells rather than via the endothelium. Thus, our data suggest that the vasodilatory response to EGF-URO is mediated via EGF-URO receptors present in the smooth muscle itself. Such receptors have previously been detected in cultures of arterial smooth muscle (15) .
We (7) and others (8) have observed that EGF-URO causes contraction of rat vascular strips in vitro. One might therefore have expected that EGF-URO administered to the intact dog would decrease regional blood flows. Yet, in the dog, in vivo, we observed an increase in flow. The in vitro observations in the dog coronary artery are, however, in keeping with the in vivo observations in that species.
In contrast with the studies with rat tissue, EGF-URO did not cause a contraction of isolated canine coronary arterial strips.
Rather, it was a potent inhibitor of the contractile response to NE. The differences between the in vitro data in the dog and rat may signal species differences in the response to EGF-URO and taken together, our data suggest: (a) that information obtained with rat vascular strips cannot be used to predict the responsiveness to EGF-URO of the vasculature of other species; and (b) that the effects of EGF-URO on blood flow in the dog arterial beds may result from its ability to modulate the resting vascular tone maintained by other agonists such as NE. The differential effects of EGF-URO in different vascular beds may, therefore, depend on the ambient autonomic tone in each bed. Because of a lack of knowledge of the precise dilution factor for the EGF-URO administered in vivo, it is not possible to compare directly the dose-response curves obtained in vivo with those obtained in vitro. Nonetheless, assuming a further 20-50-fold dilution of the dose administered in vivo, one can calculate that the concentration at the site of the resistance vessels would be in the nanomolar range, in keeping with the concentration range for the action of EGF-URO in vitro. It is also important to keep in mind that the arterial strips used for the studies in vitro were obtained from the relatively large conductance vessels and not from the much smaller calibre downstream vessels that determine vascular resistance and blood flow in vivo. Thus, the data obtained with the strips in vitro need not necessarily reflect exactly the actions of EGF-URO on the more distal resistance vessels in vivo.
In terms of responsiveness towards EGF-URO (Table II) , the arterial beds were distinct both in terms of maximum flow increase (high response: femoral and superior mesenteric; low response: carotid, coronary, celiac, and renal) and in terms of the sensitivity (ED50) towards EGF-URO (low ED50: femoral, superior mesenteric, carotid, and coronary; high ED50: celiac and renal). Because there was no correlation between maximum responsiveness and sensitivity (ED50), it was difficult to attach any mechanistic significance to these differences in the arterial responses. Further, in that arterial strips derived from the femoral artery were as responsive (maximum inhibition of agonist-mediated contraction) towards EGF-URO as were the coronaryderived strips, there did not appear to be a simple correlation between the responsiveness of the resistance vessels and the responsiveness of the larger conductance vessels. The dose-response curves like those illustrated in Figs. 2 and 4 were linearized using a double-reciprocal plot, as outlined in the text and in the legend to Fig. 3 . Values for the ED50 and E, were estimated from the reciprocals of the x-and yintercepts, respectively. The numbers in parentheses represent the number of animals used to investigate the respective vascular beds.
Of interest is the observation that the vasodilatory action of EGF-URO in the dog was not reversed by indomethacin (5 mg/ kg); in contrast indomethacin did abolish the contractile effect of EGF-URO in the rat tissue (7) . The data suggest that the action of EGF-URO in the dog vasculature, in contrast with its actions in other tissues (7, [16] [17] [18] is not mediated via products ofthe cyclooxygenase pathway. This conclusion is also supported by the data obtained in vitro, where the ability of EGF-URO to inhibit NE-mediated contraction was not affected by indomethacin (3 MM).
Both the blood flow response and the agonist-inhibitory action of EGF-URO in vitro exhibited tachyphylaxis. However, the reduced response to EGF-URO observed in vivo, either upon repeated administration or upon constant infusion (Fig. 1) could be overcome by lengthening the dose interval. The return of responsiveness in vivo may have been due to the constant perfusion ofthe tissue during the time period of tissue response. In contrast, the tachyphylaxis observed for the strips in vitro was not readily reversed. This tachyphylaxis phenomenon would be of importance in vivo where the release of EGF-URO from platelets or from tumors (see below) might cause only a transient response of the vasculature. In this regard it is of considerable interest that preliminary data obtained with transforming growth factor-alpha (a-TGF) indicate that the EGF-URO-related polypeptide does not cause tachyphylaxis in terms of the vascular response (19) . Further work is thus warranted to examine the mechanism of vascular tachyphylaxis towards EGF-URO.
In the literature there are conflicting reports of the effects of EGF-URO on the intracellular free calcium concentration. Several reports indicate either a stimulation of45Ca efflux, which is associated with an increase in intracellular Ca (8, 17, (20) (21) (22) (28) . The action of EGF-URO on tissues stimulated by transmural electrical stimulation probably reflects more accurately the situation in vivo. Evidently, EGF-URO may be able to reverse the effects of intermittent pulses of neurotransmitter released in intact tissue, whereas it cannot reverse the effect of constant exposure of the tissue to an agonist like NE applied in vitro. The inhibition of NE-mediated contraction was observed in strips equilibrated either in a Ca-free medium or in a Ca-containing medium (Fig. 5) . Taken together, these data suggest that EGF-URO in canine vascular tissue probably does not act per se as a regulator of intracellular calcium concentration. Thus, whatever the mechanism whereby EGF-URO affects the canine vascular tissue, it would appear to differ from mechanisms suggested to date that focus on the ability ofEGF-URO to raise intracellular calcium (29) , thereby causing hyperpolarization via a Ca2+-dependent K+ channel (30) . It is attractive to suggest that EGF-URO without regulating calcium levels directly, might interfere with the biochemical steps triggered by calcium to contract smooth muscle cells. One is not able however, on the basis of our experiments, to rule out the possibility that EGF-URO might interact with the mechanisms whereby an agent like NE raises intracellular calcium (Ca channel activation or mobilization ofintracellular stores via inositol trisphosphate) so as to have an indirect effect on cytoplasmic calcium levels. More experiments to determine the exact mode ofaction of EGF-URO in the canine arterial strips will be necessary. Presumably, mechanisms akin to the ones mediating the action of EGF-URO on the arterial strips in vitro may also be found to be responsible for the action of EGF-URO on the smaller resistance vessels that control blood flow in vivo.
It is an open question as to whether or not EGF-URO may play a meaningful physiological role in regulating regional blood flow in vivo. Although EGF-URO is presumed to be present in the circulation of the dog, there are as yet no good estimates of plasma levels in this species because of a lack of a suitably sensitive assay for canine EGF-URO. From serum levels estimated either in the mouse or in humans (-1 nM or lower [31, 32] ) it would appear unlikely that plasma EGF-URO per se might play a role in the minute-to-minute regulation ofregional blood flow. Nonetheless, the effects of EGF-URO on blood flow take on added significance in view of the occurrence of either EGF-URO or the EGF-URO-related polypeptides (so-called a-transforming growth factors or a-TGFs) in platelets (33) and in view of the production of these factors by tumors (34, 35) . Thus, it is possible that the physiological role for EGF-URO may be found in relation to the release by platelets of vasoactive cell regulators like EGF-URO (7, 8) and platelet-derived growth factor (27) . Even more intriguing is the possibility that tumors can produce either EGF-URO (34) or the closely related a-TGFs (34, 35) . It is known that a-TGFs acting via the EGF-URO receptor can trigger the same cellular responses caused by EGF-URO (34, 35) . This opens the exciting possibility that tumors, by secreting EGF-URO-related a-TGFs in a paracrine manner and acting via the EGF-URO receptor, may be able to regulate their own blood flow and, via this system, contribute to the local vascular hyperdynamic state associated with malignancy. Clearly, further studies on the responsiveness of arterial tissue derived from both humans and other species to EGF-URO and the EGF-
